DLBCL Clinical Trials

20 recruiting

Frequently Asked Questions

Common questions about DLBCL clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 80 trials

Recruiting
Phase 2

CAR-T Followed by Bispecific Antibodies

DLBCL - Diffuse Large B Cell LymphomaLarge B-cell Lymphoma
Abramson Cancer Center at Penn Medicine42 enrolled2 locationsNCT04889716
Recruiting
Phase 1

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Diffuse Large B-Cell Lymphoma (DLBCL)Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)+6 more
Nurix Therapeutics, Inc.572 enrolled62 locationsNCT05131022
Recruiting
Phase 1Phase 2

Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients

Diffuse Large B-Cell Lymphoma (DLBCL)Primary Mediastinal Large B-cell Lymphoma (PMBCL)Relapsed Large B-cell Lymphoma+3 more
TICAROS Co., Ltd.98 enrolled1 locationNCT07473167
Recruiting
Phase 2Phase 3

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

Diffuse Large B Cell LymphomaDLBCL
Merck Sharp & Dohme LLC290 enrolled116 locationsNCT05139017
Recruiting
Phase 3

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

Non-Hodgkin LymphomaRefractory Non-Hodgkin LymphomaLymphoma, B-Cell+6 more
Lyell Immunopharma, Inc.400 enrolled39 locationsNCT07188558
Recruiting
Phase 1Phase 2

Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma

DLBCL - Diffuse Large B Cell LymphomaLymphomaLymphoplasmacytic Lymphoma+5 more
ModeX Therapeutics, An OPKO Health Company180 enrolled1 locationNCT07249905
Recruiting
Phase 1

P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

High-grade B-cell LymphomaDLBCL - Diffuse Large B Cell LymphomaPrimary Mediastinal Large B-cell Lymphoma (PMBCL)+7 more
Poseida Therapeutics, Inc.120 enrolled17 locationsNCT06014762
Recruiting
Phase 2

Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

Diffuse Large B Cell LymphomaNHLNon-Hodgkin's Lymphoma+1 more
National Cancer Institute (NCI)132 enrolled1 locationNCT04002947
Recruiting
Phase 1Phase 2

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

Breast CancerLiver CancerNon-small Cell Lung Cancer (NSCLC)+10 more
Essen Biotech85 enrolled1 locationNCT07410494
Recruiting
Early Phase 1

Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

Diffuse Large B Cell LymphomaB-ALLDLBCL Unclassifiable+7 more
Memorial Sloan Kettering Cancer Center12 enrolled7 locationsNCT04512716
Recruiting
Phase 1

Study of SGR-1505 in Mature B-Cell Neoplasms

High-grade B-cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+23 more
Schrödinger, Inc.98 enrolled36 locationsNCT05544019
Recruiting
Phase 1

This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma

DLBCL - Diffuse Large B Cell LymphomaFollicular Lymphoma ( FL)Mantle Cell Lymphoma (MCL)+2 more
LTZ Therapeutics, Inc.42 enrolled5 locationsNCT07121946
Recruiting
Phase 2

A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma

DLBCL
University of Rochester40 enrolled1 locationNCT03758989
Recruiting
Phase 2

CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL

Diffuse Large B-Cell Lymphoma (DLBCL)
Tianjin Medical University Cancer Institute and Hospital58 enrolled1 locationNCT07397832
Recruiting

Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms

Diffuse Large B-Cell Lymphoma (DLBCL)Chronic Lymphocytic Leukemia (CLL)Follicular Lymphoma ( FL)+3 more
iOMEDICO AG2,950 enrolled1 locationNCT06043011
Recruiting
Phase 2

Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+

Diffuse Large B Cell LymphomaDLBCL - Diffuse Large B Cell Lymphoma
Virginia Commonwealth University21 enrolled1 locationNCT06846463
Recruiting
Phase 2

Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma

Diffuse Large B-Cell Lymphoma (DLBCL)
Beijing Tongren Hospital50 enrolled1 locationNCT07371923
Recruiting
Not Applicable

Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors

Classical Hodgkin LymphomaDiffuse Large B-Cell Lymphoma (DLBCL)Primary Mediastinal Large B-cell Lymphoma (PMBCL)
Fondazione Italiana Linfomi - ETS552 enrolled40 locationsNCT05934084
Recruiting
Phase 1

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

Lymphoma, B-CellChronic Lymphocytic Leukemia (CLL)Lymphoma, Non-Hodgkin (NHL)+1 more
Umoja Biopharma106 enrolled8 locationsNCT06528301
Recruiting
Phase 2

DALY II Japan/MB-CART2019.1 for DLBCL

DLBCL - Diffuse Large B Cell LymphomaCAR-T Cell Therapy
Miltenyi Biomedicine GmbH31 enrolled5 locationsNCT07288879